Ask AI
ProCE Banner Activity

Navigating Patient Conversations on Adjuvant CDK4/6 Inhibitors in High-Risk HR+/HER2− Early Breast Cancer: Insights for Pharmacists

Clinical Thought

Gain expert insights from a recent live symposium with a focus on common questions oncology pharmacists face as CDK4/6 inhibitors become more widely incorporated into the adjuvant treatment paradigm for HR-positive/HER2-negative early breast cancer.

Released: May 06, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for oncology pharmacists and other healthcare professionals involved in the management of patients with high-risk HR-positive, HER2-negative EBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret key efficacy endpoints, including IDFS and OS, from pivotal adjuvant CDK4/6 inhibitor trials and apply these data to appropriate, guideline-aligned use in high-risk HR+/HER2- EBC 

  • Implement evidence-based, pharmacist-led strategies to support patient selection and personalization of adjuvant CDK4/6 inhibitor therapy, incorporating individual risk factors, treatment goals, and regimen duration 

  • Proactively identify, monitor, and manage treatment-related toxicities, including appropriate dose modification strategies, to maintain therapeutic intent while supporting adherence and persistence with long-duration oral therapy 

  • Apply effective patient and multidisciplinary communication approaches to reinforce adherence, persistence, and shared decision-making throughout the adjuvant CDK4/6 treatment course 

Faculty Disclosure

Primary Author

Rodney Hunter, PharmD, BCOP: consultant/advisor/speaker: Lilly Oncology.

Julia L. Ziegengeist, PharmD, BCOP, has no relevant financial relationships to disclose.